Alemtuzumab: egy új terápia előnyei és kihívásai sclerosis multiplexben

Translated title of the contribution: ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS

Zsolt Illés, Tobias Sejbaek, Tünde Csépány

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The widening spectrum of MS treatment is partially due to increasing knowledge about the pathogenesis of MS. The humanized monoclonal antibody against CD52, alemtuzumab has been approved in Europe for the treatment of MS, which results in long-term depletion of B and T cells due to complement- and antibody-mediated cytotoxicity. Based on phase 2 and 3 clinical trials, alemtuzumob decreases the risk of sustained neurological deficit and progression compared to high-dose subcutaneous interferon-β1a in patients with active relapsing-remitting MS, either treatment-naïve or with breakthrough disease. We review advantages and benefits of the treatment, discuss safety concerns, and present a case to describe practical issues.

Original languageUndefined/Unknown
JournalIdeggyogyaszati Szemle
Volume68
Issue number5-6
Pages (from-to)155-164
ISSN0019-1442
DOIs
Publication statusPublished - 2015

Fingerprint

Phase III Clinical Trials
Safety

Cite this

@article{37bffbae147b4575aa4922694ad4739a,
title = "Alemtuzumab: egy {\'u}j ter{\'a}pia előnyei {\'e}s kih{\'i}v{\'a}sai sclerosis multiplexben",
abstract = "The widening spectrum of MS treatment is partially due to increasing knowledge about the pathogenesis of MS. The humanized monoclonal antibody against CD52, alemtuzumab has been approved in Europe for the treatment of MS, which results in long-term depletion of B and T cells due to complement- and antibody-mediated cytotoxicity. Based on phase 2 and 3 clinical trials, alemtuzumob decreases the risk of sustained neurological deficit and progression compared to high-dose subcutaneous interferon-β1a in patients with active relapsing-remitting MS, either treatment-na{\"i}ve or with breakthrough disease. We review advantages and benefits of the treatment, discuss safety concerns, and present a case to describe practical issues.",
keywords = "Adjuvants, Immunologic, Adult, Antibodies, Monoclonal, Humanized, Brain, Clinical Trials as Topic, Disease Progression, Drug Administration Schedule, Europe, Female, Humans, Interferon beta-1a, Interferon-beta, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Myelitis, Transverse, Spinal Cord, Treatment Outcome",
author = "Zsolt Ill{\'e}s and Tobias Sejbaek and T{\"u}nde Cs{\'e}p{\'a}ny",
year = "2015",
doi = "10.18071/isz.68.0155",
language = "Udefineret/Ukendt",
volume = "68",
pages = "155--164",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Literatura Medica Kiado",
number = "5-6",

}

Alemtuzumab : egy új terápia előnyei és kihívásai sclerosis multiplexben. / Illés, Zsolt; Sejbaek, Tobias; Csépány, Tünde.

In: Ideggyogyaszati Szemle, Vol. 68, No. 5-6, 2015, p. 155-164.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Alemtuzumab

T2 - egy új terápia előnyei és kihívásai sclerosis multiplexben

AU - Illés, Zsolt

AU - Sejbaek, Tobias

AU - Csépány, Tünde

PY - 2015

Y1 - 2015

N2 - The widening spectrum of MS treatment is partially due to increasing knowledge about the pathogenesis of MS. The humanized monoclonal antibody against CD52, alemtuzumab has been approved in Europe for the treatment of MS, which results in long-term depletion of B and T cells due to complement- and antibody-mediated cytotoxicity. Based on phase 2 and 3 clinical trials, alemtuzumob decreases the risk of sustained neurological deficit and progression compared to high-dose subcutaneous interferon-β1a in patients with active relapsing-remitting MS, either treatment-naïve or with breakthrough disease. We review advantages and benefits of the treatment, discuss safety concerns, and present a case to describe practical issues.

AB - The widening spectrum of MS treatment is partially due to increasing knowledge about the pathogenesis of MS. The humanized monoclonal antibody against CD52, alemtuzumab has been approved in Europe for the treatment of MS, which results in long-term depletion of B and T cells due to complement- and antibody-mediated cytotoxicity. Based on phase 2 and 3 clinical trials, alemtuzumob decreases the risk of sustained neurological deficit and progression compared to high-dose subcutaneous interferon-β1a in patients with active relapsing-remitting MS, either treatment-naïve or with breakthrough disease. We review advantages and benefits of the treatment, discuss safety concerns, and present a case to describe practical issues.

KW - Adjuvants, Immunologic

KW - Adult

KW - Antibodies, Monoclonal, Humanized

KW - Brain

KW - Clinical Trials as Topic

KW - Disease Progression

KW - Drug Administration Schedule

KW - Europe

KW - Female

KW - Humans

KW - Interferon beta-1a

KW - Interferon-beta

KW - Magnetic Resonance Imaging

KW - Multiple Sclerosis

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Myelitis, Transverse

KW - Spinal Cord

KW - Treatment Outcome

U2 - 10.18071/isz.68.0155

DO - 10.18071/isz.68.0155

M3 - Tidsskriftartikel

C2 - 26182606

VL - 68

SP - 155

EP - 164

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 5-6

ER -